Skip to main content

Table 3 Relative risk of breast cancer and 95% confidence intervals according to genotype of ATM haplotype tagging single nucleotide polymorphisms (SNPs) in the Nurses' Health Study (1989–2000)

From: Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: a nested case–control study

SNP

Genotype

Casesa

Controlsa

Relative riskb

Relative riskc

SNP1

T/T

450 (35.3)

556 (33.9)

1.00 (Reference)

1.00 (Reference)

 

T/A

575 (45.1)

762 (46.4)

0.94 (0.79–1.11)

0.94 (0.79–1.12)

 

A/A

249 (19.5)

324 (19.7)

0.95 (0.77–1.17)

0.94 (0.75–1.17)

SNP2

A/A

1158 (90.5)

1495 (90.5)

1.00 (Reference)

1.00 (Reference)

 

A/C

118 (9.2)

154 (9.3)

1.00 (0.77–1.30)

1.02 (0.78–1.34)

 

C/C

4 (0.3)

3 (0.2)

1.64 (0.36–7.45)

2.07 (0.42–10.26)

SNP3

G/G

455 (35.8)

553 (34.3)

1.00 (Reference)

1.00 (Reference)

 

G/A

570 (44.9)

755 (46.8)

0.99 (0.83–1.17)

0.99 (0.83–1.18)

 

A/A

245 (19.3)

306 (19.0)

1.03 (0.83–1.28)

1.03 (0.82–1.29)

SNP4

A/A

164 (12.7)

189 (11.0)

1.00 (Reference)

1.00 (Reference)

 

A/C

565 (43.9)

759 (44.0)

0.88 (0.69–1.12)

0.87 (0.68–1.12)

 

C/C

559 (43.4)

778 (45.1)

0.86 (0.67–1.09)

0.85 (0.66–1.09)

SNP5

C/C

970 (75.7)

1207 (73.1)

1.00 (Reference)

1.00 (Reference)

 

C/A

292 (22.8)

417 (25.2)

0.87 (0.73–1.04)

0.86 (0.72–1.04)

 

A/A

20 (1.6)

28 (1.7)

0.81 (0.45–1.47)

0.81 (0.44–1.50)

  1. a Data presented as n (%). Numbers may not add to totals due to missing genotype data. b Relative risks are crude odds ratios from conditional logistic regression models (95% confidence interval). c Relative risks (95% confidence interval) are from conditional logistic regression models adjusted for age at menarche (< 12 years, 12 years, 13 years, > 13 years), age at menopause (≤ 45 years, 46–50 years, 51–60 years), first-degree family history of breast cancer (yes/no), personal history of benign breast disease (yes/no), weight gain since age 18 (< 5 kg, ≥ 5 to < 20 kg, ≥ 20 kg), body mass index at age 18 (continuous), age at first birth/parity (nulliparous, one to four children/age at first birth ≤ 24 years, one to four children/age at first birth > 24 years, five or more children/age at first birth ≤ 24 years, five or more children/age at first birth > 24 years), and duration of postmenopausal hormone use (premenopausal, never, past user < 5 years duration, past user ≥ 5 years duration, current user < 5 years duration, current user ≥ 5 years duration).